Dear Batten community,
As many of you know, we have been awaiting further news regarding the future of the CLN3 and CLN6 gene therapy clinical programs led by Amicus Therapeutics. Today, we wish to share an important update relating to both programs. In a Letter to the Community, Amicus has advised that it has decided to return the rights to all Batten programs to The Abigail Wexner Research Institute at Nationwide Children’s Hospital (NCH), which includes the CLN3 and CLN6 clinical programs as well as the CLN8 preclinical program. As such, NCH is now responsible for determining the next steps in developing those programs and for all follow-up with the CLN3 and CLN6 clinical trial participants and their families. A copy of the Community Letter from Amicus can be viewed here.
NCH has reassured our community that it remains committed to moving its CLN3 and CLN6 programs forward. Dr. Emily de los Reyes at NCH has provided further details on those plans in a separate Community Letter, which can be viewed here.
Warm regards,
